Bristol Myers Squibb accused of buying off competitors to delay development of generic cancer drugs
A healthcare provider says Bristol Myers Squibb overcharged for Thalidomide and Revlimid after paying erstwhile generic competitors to delay entry until January 2026 or later.
Original Source
Read the full article at Courthousenews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.